Stratifying Alopecia Areata Systemic Treatments: Tailored Approaches to Disease Severity

    July 2024 in “ Journal of Investigative Dermatology ”
    Simonetta I. Gaumond, Rama Abdin, J.J. Jimenez
    TLDR Tailored treatments for alopecia areata show promising results, with pulse steroids effective for mild cases and Ritlecitinib, Dupilumab, or methotrexate and prednisone effective for severe cases.
    Alopecia areata (AA) affects 145 million people globally and varies in severity from localized to complete hair loss. This literature review analyzed 12 clinical trials on systemic therapies for AA over the past decade. For localized AA, pulse steroid therapy showed an 81.3% favorable response. Moderate-to-severe AA responded best to the JAK-3 inhibitor Ritlecitinib, with 50% achieving SALT30 at 24 weeks. Severe AA showed optimal responses with Ritlecitinib, Dupilumab, or methotrexate and prednisone combination, with Ritlecitinib and Dupilumab achieving SALT20 and SALT30 improvements in 31% and 32.5% of patients, respectively. Methotrexate and prednisone led to 31% complete hair regrowth. Further studies are needed to explore long-term outcomes and treatment cessation effects.
    Discuss this study in the Community →